Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/TheBodyPRO.com cover the XIX International AIDS Conference (AIDS 2012)
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
Prevention/Epidemiology

Researchers to Test Monthly Vaginal Ring for HIV Prevention

July 25, 2012

Two large clinical HIV-prevention trials in Africa will test the safety and effectiveness of a vaginal ring containing the antiretroviral drug dapivirine. Both studies are being conducted in partnership with the US National Institutes of Health-backed Microbicide Trials Network.

If effective, the ring will add "a long-acting, female-initiated technology to the existing toolkit of HIV prevention options," said Dr. Zelda Rosenberg, CEO of the International Partnership for Microbicides (IPM), a nonprofit group that is developing the ring. Because it only needs to be replaced once a month, the ring may help address some of the problems with getting women to use vaginal gels consistently each time they have sex, Rosenberg said during the 19th International AIDS Conference.

The IPM study will enroll 1,100 women ages 18-45 at four sites in South Africa; they will be randomly assigned to use the ring or a placebo. Researchers plan to expand the trial to Rwanda and Malawi.

Advertisement
The other study, called ASPIRE, will test the ring in 3,476 women ages 18-45 in Malawi, South Africa, Uganda, Zambia, and Zimbabwe.

Dapivirine is part of a class of antiretroviral drugs that have long been used to treat HIV and prevent mother-to-child HIV transmission.

Results are expected in 2015. Both trials are seeking at least a 60 percent reduction in HIV risk, but researchers hope for an even better outcome.

"Because the vaginal ring is a long-acting intervention, it has a potential added benefit in that women may find it relatively easy to use," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

Women in the studies will be offered condoms and HIV prevention counseling. Women who become pregnant will discontinue use of the ring and will continue to be monitored.

Back to other news for July 2012

Adapted from:
Reuters
07.25.2012; Julie Steenhuysen


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
AIDS 2012 Research & Clinical Coverage

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


Advertisement